Abstract:Human immunodeficiency virus (HIV)-specific cytotoxic T lymphocytes (CTL) are an important parameter of host defenses that limit viral replication after infection. Induction of effective CTL against conserved viral proteins such as Gag may be essential to the development of a safe and effective HIV type 1 (HIV-1) vaccine. DNA vaccination represents a novel strategy for inducing potent CD8(+) CTL responses in vivo. However, expression of HIV-1 structural proteins by DNA vectors has been hampered by a stringent requirement for coexpression with other viral components, such as Rev and RRE. Furthermore, even with Rev and RRE present, the level of expression of HIV-1 Gag, pol, or Env is very low in murine cells. These problems have limited our ability to address the key issue of how to generate effective CTL responses to Gag in a mouse model. To overcome this problem, we compared several novel DNA expression vectors for HIV-1 Gag protein expression in primate and mouse cells and for generating immune responses in mice after DNA vaccination. A DNA vector containing wild type HIV-1 gag coding sequences did not induce detectable Gag expression in any of the cells tested. Attempts to increase nuclear export of Gag expression RNA by adding the constitutive transport element yielded only a moderate increase in Gag expression in monkey-derived COS cells and an even lower increase in Gag expression in HeLa cells or several mouse cell lines. In contrast, silent-site mutations in the HIV-1 gag coding sequences significantly increased Gag expression levels in all cells tested. Furthermore, this construct induced both Gag-specific antibody and CTL responses in mice after DNA vaccination. Using this construct, we achieved stable expression of HIV-1 Gag in the mouse cell line p815, which can now be used as a target cell for measuring HIV-1 Gag-specific CTL responses in immunized mice. The DNA vectors described in this study should make it possible to systematically evaluate the approaches for maximizing the induction of CTL responses against HIV-1 Gag in mouse and other animal systems.

Fusion Expression of Mouse IgG2b-Fc Improves Immunogenicity of Human Immunodeficiency Virus Type 1 Gag DNA Vaccine

Enhancement of Primary and Secondary Cellular Immune Responses Against Human Immunodeficiency Virus Type 1 Gag by Using DNA Expression Vectors That Target Gag Antigen to the Secretory Pathway

Evaluation Of Novel Human Immunodeficiency Virus Type 1 Gag Dna Vaccines For Protein Expression In Mammalian Cells And Induction Of Immune Responses

Increasing a robust antigen-specific cytotoxic T lymphocyte response by FMDV DNA vaccination with IL-9 expressing construct.

Immunogenicity of DNA Vaccines Encoding Structural Proteins and Regulatory/accessory Proteins Derived from an HIV-1 CRF01_AE Isolate Circulating in China

Construction and Expression of the Eukaryotic Expression Vector Pci-Chil-2-egfp and Enhancement of AIV Vaccine

Expression and Identification of Immunological Activities of the HIV‐gp120N‐Human Interferon Gamma Fusion Protein

Enhancing immune responses against HIV-1 DNA vaccine by coinoculating IL-6 expression vector.

[Study on the Immunogenicity of HIV-1 Gag Vaccine].

Construction and Immunology of HIV-2 Gp105 and / or Gag DNA Vaccine

Combined Immunization of HIV-2 Group Antigen Gene Recombinant Vaccines Inflict Higher Immune Response

Combined immunization of mice with DNA, rMVA and rAd5 expressing HIV-1 structural genes from different subtypes.

A Δ42PD1 fusion-expressing DNA vaccine elicits enhanced adaptive immune response to HIV-1: the key role of TLR4

[Immune Response Induced by HIV DNA Vaccine Combined with Recombinant Adeno-Associated Virus].

[Immune Response to HIV-2 Gp105 DNA Vaccine in Mice].

Cellular and humoral immne reponses induced by HIV-2 recombinant fowlpox virus on mice

[The Immune Response in Mice Inoculated with HIV-1 Gag-Gp120 Chimeric Gene DNA Vaccine and IL-18 Plasmid].

Experimental immunization study on HIV-2 core DNA vaccine

Expression and Immunogenicity of Two Recombinant Fusion Proteins Comprising Foot-and-Mouth Disease Virus Structural Protein VP1 and DC-SIGN-Binding Glycoproteins

Immunogenicities and comparison of DNA vaccines encoding pol genes derived from B｀/C and A/E recombinant HIV-1 strains

DNA Vaccines Expressing Glycoprotein Complex II Antigens Gm and Gn Elicited Neutralizing Antibodies Against Multiple Human Cytomegalovirus (HCMV) Isolates.